Rallybio Corp (RLYB): restructuring charge — Rallybio cuts 45% of workforce, extends cash runway to mid-2026

Rallybio Corp

Workforce reduction of 45% (19 positions); expects ~$3.3M in severance charges.
Preliminary cash, equivalents and marketable securities of $109.9M as of Dec 31, 2023.
Prioritizes Phase 2-ready programs RLYB212 (FNAIT) and RLYB116 (C5 inhibitor).
Cash runway extended into mid-2026; preclinical programs seek alternative funding.
RLYB212 Phase 2 update with EMA expected H1 2024; Phase 2 initiation in H2 2024.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Rallybio Corp announced a restructuring with charges of approximately $3.3 million affecting Rallybio (approximately 45% of its current positions).

Type: restructuring
Charge: approximately $3.3 million
Affected area: Rallybio
Headcount: approximately 45% of its current positions

Exact text from the filing

On February 6, 2024, Rallybio announced the prioritization of its portfolio and a workforce reduction to focus resources on its Phase 2-ready clinical stage programs, RLYB212 and RLYB116. As part of this effort, Rallybio will eliminate approximately 45% of its current positions. As a result of these actions, Rallybio expects to incur charges of approximately $3.3 million, excluding share-based compensation expense.

View on SEC.gov

Browse all restructurings & charges →

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0001739410-24-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.